FDA Cites Avonex Comparative Promotions; Biogen Challenges Findings

FDA is asking Biogen to stop using the words "short- term" and "long-term" in promotional materials comparing its multiple sclerosis therapy Avonex (interferon beta-1a) with Serono's Rebif (interferon beta-1a)